MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/10600280261456308

Медицинская библиотека · The Annals of pharmacotherapy · 2026

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

Lahoud Jeanette, Jacobs Josephine, Ratrut Lauren, Kitten Amanda, Franco-Martinez Crystal

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Apixaban and rivaroxaban, direct oral anticoagulants (DOACs) used for acute venous thromboembolism (VTE) treatment, require higher dose lead-in periods of 7 days and 21 days, respectively. The optimal lead-in duration for patients receiving more than 48 hours of parenteral anticoagulation (AC) is unclear. In addition, guidelines lack recommendations for high bleed-risk patients who might benefit from a shortened lead-in.

OBJECTIVE

This study aimed to evaluate the effectiveness and safety of a modified lead-in strategy, where parenteral AC counts toward shortening or eliminating the DOAC lead-in period, compared to a full lead-in strategy, where a 7-day apixaban or 21-day rivaroxaban lead-in is prescribed irrespective of parenteral AC received.

METHODS

A retrospective cohort study analyzed patients diagnosed with an acute VTE during hospitalization. Patients were grouped based on a modified versus full lead-in strategy. Primary outcomes of recurrent VTE (rVTE) and bleeding were evaluated at 90 days.

RESULTS

Of 101 included patients, 47 were in the modified lead-in group and 54 in the full lead-in group. Patients in the modified lead-in group had a higher risk of bleeding at baseline. Recurrent VTE occurred in 4 patients in the modified lead-in group, compared to 2 patients in the full lead-in group (9% vs 4%; P = .4129). Bleeding occurred in 10 patients in the modified lead-in group, compared to 3 patients in the full lead-in group (21% vs 6%; P = .0167).

CONCLUSION AND RELEVANCE: No significant difference in rVTE was observed between groups. The modified lead-in group had a higher incidence of bleeding, possibly reflecting greater baseline risk and clinical complexity rather than the modification itself. Modified lead-in strategies may be reasonable in select patients, particularly those at high risk for bleeding; however, larger studies are needed to confirm safety and efficacy.

Для цитирования: Lahoud Jeanette, Jacobs Josephine, Ratrut Lauren, Kitten Amanda, Franco-Martinez Crystal. Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.. The Annals of pharmacotherapy. 2026. DOI: 10.1177/10600280261456308.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.